Department of Medicine, Surgery and Neurosciences, Respiratory Diseases and Lung Transplantation Section, University of Siena, Viale Bracci, 1, 53100, Siena, Italy.
Inflammation. 2020 Apr;43(2):393-400. doi: 10.1007/s10753-019-01157-0.
Asthma is an immunoinflammatory disease characterized by bronchial hyper-reactivity to different external stimuli. New monoclonal target treatments have been developed, but few studies have investigated the role of regulatory T cells in severe asthma and the modulatory effect of biological therapy on regulatory T cell functions. Their dysfunction may contribute to the development and exacerbation of asthma. Here we review the recent literature on the potential immunological role of regulatory T cells in the pathogenesis of severe asthma. The analysis of the role of regulatory T cells was performed in terms of functions and their possible interactions with mechanisms of action of the novel treatment for severe asthma. In an era of biological therapies for severe asthma, little data is available on the potential effects of what could be a new therapy: monoclonal antibody targeting of regulatory T cell numbers and functions.
哮喘是一种免疫炎症性疾病,其特征是支气管对不同的外部刺激物呈现超反应性。已经开发出了新的单克隆靶向治疗方法,但很少有研究调查调节性 T 细胞在严重哮喘中的作用以及生物疗法对调节性 T 细胞功能的调节作用。它们的功能障碍可能导致哮喘的发展和恶化。在这里,我们回顾了关于调节性 T 细胞在严重哮喘发病机制中潜在免疫作用的最新文献。根据调节性 T 细胞的功能及其与严重哮喘新型治疗方法作用机制的可能相互作用,对其进行了分析。在严重哮喘的生物治疗时代,针对调节性 T 细胞数量和功能的单克隆抗体靶向治疗可能会产生潜在影响,但目前关于这方面的数据很少。